Jubilant Ingrevia Limited - Comprehensive FY26 Annual Report and AGM Notice

Financial Performance Highlights

Jubilant Ingrevia reported strong financial results for FY26 with standalone net profit of ₹2,679.91 million (up 5% YoY) and revenue from operations of ₹41,384.88 million. Consolidated performance showed profit attributable to owners of ₹2,778.99 million with basic EPS of ₹17.59. The company achieved EBITDA of ₹607 crore (+9% YoY) with 14% margin, while maintaining net debt/EBITDA at 0.99x and working capital days at 59.

Dividend Declaration and Corporate Actions

The Board recommended a final dividend of ₹2.50 per share, bringing total FY26 dividend to ₹5.00 per share (500%) amounting to approximately ₹796 million payout. Key corporate actions included:

  • Acquisition of 100% stake in Remidex Pharma Private Limited for ₹162.79 million to enhance human nutrition and pharma manufacturing capabilities
  • ESOP trust purchased 503,848 shares during FY26 with 94,616 shares transferred to employees upon option exercises
  • Commissioning of multipurpose Agro CDMO facility at Bharuch with first despatches in March 2026

7th Annual General Meeting Details

The company issued notice for its 7th AGM scheduled for August 26, 2026, to be held virtually through VC/OAVM. Agenda includes:

  • Adoption of FY26 standalone and consolidated financial statements
  • Declaration of final dividend of ₹2.50 per share
  • Reappointment of Mr. Shyam S. Bhartia and Mr. Priyavrat Bhartia as directors
  • Ratification of cost auditor remuneration for M/s J.K. Kabra & Co. at ₹4,75,000 plus taxes

Sustainability and ESG Performance

The comprehensive BRSR report highlighted significant sustainability achievements:

  • Reduced GHG emission intensity to 1.49 tCO2e/MT (target: 1.51)
  • Lowered specific water consumption to 6.27 KL/MT (target: 6.40)
  • Increased women workforce representation to 7.2% (target: 12% by FY27)
  • Maintained zero fatalities and Lost Time Injury Frequency Rate
  • Achieved S&P Global CSA score of 74/100 (97th percentile in Chemicals)
  • Implemented Zero Liquid Discharge at 3 out of 5 manufacturing sites

Segment Performance Analysis

Specialty Chemicals: Revenue ₹1,937 crore (+7%), EBITDA ₹510 crore (+21%), 26% margin

Nutrition & Health Solutions: Revenue ₹790 crore (+6%), EBITDA ₹100 crore

Chemical Intermediates: Revenue ₹1,662 crore (+3%), EBITDA ₹73 crore

Geographical revenue mix showed India contributing 59.55% (₹24,651.90 million), America and Europe 28.75% (₹11,901.02 million), with remaining from China and rest of world.

Regulatory Compliance and Governance

The company fully complied with SEBI BRSR and LODR requirements, with auditors Walker Chandiok & Co LLP issuing unmodified opinions. Key audit matters addressed revenue recognition and capitalization of property, plant & equipment. The Board composition includes independent directors and female representation, with robust governance structure overseeing sustainability initiatives.

Exceptional Items and Contingencies

The company recognized ₹122.21 million exceptional expense due to implementation of new Labour Codes effective November 2025, impacting employee benefits computation. Contingent liabilities totaled ₹4,536.66 million, primarily related to income tax (₹1,762.58 million) and state excise (₹1,667.86 million) disputes.

Future Outlook and Strategic Initiatives

The company continues to focus on specialty chemicals growth, renewable energy partnerships (including 28% stake in O2 Renewable Energy), and expanding nutrition business through the Remidex acquisition. Sustainability targets include achieving >35% renewable energy by FY29 and further reducing environmental footprint across operations.